Benzene and Acute Myeloid Leukemia: Clinical Evidence Review

From General Awareness to Occupational Focus

The legacy of general health and science information has long served as a foundation for public understanding of environmental risks, emphasizing broad awareness of chemical hazards and their potential to affect human well-being. Within this framework, discussions of benzene exposure have historically centered on its presence in everyday settings—such as gasoline fumes, cigarette smoke, and industrial emissions—highlighting general precautions for the population at large. This heritage provides a critical baseline for recognizing benzene as a recognized health concern, yet it often lacks the specificity required to address the concentrated risks faced by certain groups. As we pivot from this general context to a more focused occupational exposure concern, the transition becomes necessary to examine how routine workplace environments can amplify these hazards. In mass production settings, where benzene is frequently used as a solvent or intermediary in manufacturing processes, workers may encounter sustained contact at levels far exceeding those in ambient air. This shift in perspective moves beyond population-level advisories to consider the practical realities of daily exposure in factories, refineries, and chemical plants.

Clinical Evidence Linking Benzene to Acute Myeloid Leukemia

Benzene is a recognized myelotoxin and carcinogen, with chronic exposure linked to an increased risk of acute myeloid leukemia (AML) and other hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, infection, and bleeding, and diagnosis is confirmed by peripheral blood and bone marrow examination showing at least 20% myeloid blasts. Benzene exposure can augment the risk for AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). Mechanistically, benzene initiates hematological tumors through genotoxic effects, oxidative stress and inflammation, and immunosuppression, though genetic alterations alone are insufficient to fully explain the onset of these malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). The mode of action for AML development includes multiple earlier key events, such as hematotoxicity and genetic toxicity in peripheral blood of exposed workers, and preventing these early events would prevent the apical adverse outcomes of morbidity and mortality from myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Previous studies have established a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). In a Swiss National Cohort study, mortality records linked to census data were used to assess occupational benzene exposure via a quantitative job-exposure matrix, examining associations with lymphohaematopoietic cancer mortality (https://pubmed.ncbi.nlm.nih.gov/38727681/). A meta-analysis of 25 studies found that benzene exposure was associated with an increased risk of childhood AML, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). This finding underscores the risk even at relatively low environmental exposure levels.

Risk Assessment and Causation Considerations

For risk assessment, combining data from human AML studies, human leukemia studies, human biomarker studies, and experimental animal studies allows estimation of the exposure-response relation between benzene and AML (https://pubmed.ncbi.nlm.nih.gov/34906966/). A linear meta-regression model best predicted AML risks, using summary risk estimates from non-AML and nonhuman studies as prior information (https://pubmed.ncbi.nlm.nih.gov/34906966/). Regarding adequacy of warnings, the evidence indicates that benzene's carcinogenic ability has been reported, and it is acknowledged as a myelotoxin that can augment AML risk (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, the specific adequacy of warnings in occupational or consumer settings is not directly addressed in the provided evidence. For causation considerations, affected patients should be evaluated for history of benzene exposure, as occupational exposure at levels of 10 ppm or more is associated with increased AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). The timeline between exposure and documented harm can vary; the mode of action includes multiple key events that may occur over years, with early hematotoxicity and genetic toxicity observable in peripheral blood before AML develops (https://pubmed.ncbi.nlm.nih.gov/33429013/). The exposure-response curve for benzene and AML can be estimated using integrated data from multiple study types, supporting a linear relationship (https://pubmed.ncbi.nlm.nih.gov/34906966/). In summary, the clinical evidence supports a causal link between benzene exposure and AML, with mechanistic pathways involving genotoxicity, oxidative stress, and immunosuppression. Risk models incorporating key event information can improve assessment, and affected patients should be evaluated for exposure history. The timeline from exposure to AML may span years, with early hematologic changes preceding disease onset.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the clinical evidence linking benzene to acute myeloid leukemia?

Benzene is a recognized myelotoxin and carcinogen. Chronic exposure is linked to increased risk of AML and other hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure at levels of 10 ppm or more is associated with increased AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). Mechanistically, benzene causes genotoxic effects, oxidative stress, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/).

How is the risk of AML from benzene exposure assessed?

Risk assessment combines data from human AML studies, leukemia studies, biomarker studies, and animal studies to estimate the exposure-response relation (https://pubmed.ncbi.nlm.nih.gov/34906966/). A linear meta-regression model best predicts AML risks (https://pubmed.ncbi.nlm.nih.gov/34906966/).

What is the typical timeline from benzene exposure to AML development?

The mode of action includes multiple key events over years, with early hematotoxicity and genetic toxicity observable in peripheral blood before AML develops (https://pubmed.ncbi.nlm.nih.gov/33429013/). The timeline may span years.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.